Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

Medically reviewed by Steffini Stalos, DO Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the ...

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

This blog explores the benefits of applying Large Language Models to extract information from pathology reports, allowing us to curate bespoke ...

established at SGH in October 2023 to standardise care for the 40 to 50 new high-risk bladder cancer patients each year, aims to advance the understanding of the disease and find novel treatments to ...

SINGAPORE – A combination of two existing chemotherapy drugs has been used to fight bladder cancer successfully for ... outcomes while keeping costs low. Dr Tan said that most importantly ...

Many patients face life-altering surgical options such as radical cystectomy, which is complete bladder removal,” said Yusri ... tolerability data presented at ESMO demonstrated a low occurrence of ...

Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice. Like all cancers ...

If you're studying stool microbiome in patients who are receiving cancer therapy, whether it's chemotherapy or immunotherapy, just knowing what bugs are different and associating that to a better ...

Bladder cancer patients treated with a breakthrough drug are a third less likely to see their disease return and have higher survival rates, a major new study has revealed. The immunotherapy drug ...

but yet the level of awareness about bladder cancer in the UK remains low.” The trial was funded by AstraZeneca, with the results published in the New England Journal of Medicine. At the the ...